Early research (Phase 1)Ended earlyNCT06560645
What this trial is testing
PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Who this might be right for
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Carcinoma+7 more
Prelude Therapeutics Incorporated 42